Eckels K H, Harrison V R, Summers P L, Russell P K
Infect Immun. 1980 Jan;27(1):175-80. doi: 10.1128/iai.27.1.175-180.1980.
The S-1 clone of dengue type 2 virus was used for the preparation of a live-attenuated vaccine after passage in DBS-FRhL-2 cell culture. The vaccine virus had a relatively higher replicative capacity at superoptimal temperatures than its precursor virus, S-1, passaged in primary green monkey kidney cells (S-1 PGMK). There was also a tendency for the S-1 vaccine virus to exhibit leakiness at increased temperatures. Another in vitro marker, replication in monkey peripheral blood leukocytes, indicated less host restriction for the S-1 vaccine in comparative assays with S-1 PGMK virus. Mouse virulence appeared to remain stable on passage in DBS-FRhL-2 cells, whereas monkey immunogenicity decreased. Cautious trials of the dengue type 2 S-1 vaccine in humans are indicated.
登革2型病毒的S-1克隆株在DBS-FRhL-2细胞培养中传代后用于制备减毒活疫苗。该疫苗病毒在超适宜温度下比其在原代绿猴肾细胞（S-1 PGMK）中传代的前体病毒S-1具有相对更高的复制能力。S-1疫苗病毒在温度升高时也有表现出渗漏的趋势。另一个体外标志物，即在猴外周血白细胞中的复制，表明在与S-1 PGMK病毒的比较试验中，S-1疫苗对宿主的限制较小。小鼠毒力在DBS-FRhL-2细胞传代过程中似乎保持稳定，而猴免疫原性则降低。因此建议对登革2型S-1疫苗进行谨慎的人体试验。
